Clinical Trial Update: Using Biomarkers to Predict TB Treatment Duration [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating biomarkers to predict duration of pulmonary tuberculosis treatment; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Pulmonary Tuberculosis | Phase 2 | Status: COMPLETED | Results posted: 2022-12-20